Published in Indian J Surg on May 23, 2015
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14
Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med (1996) 6.01
Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg (2003) 5.61
Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg (2000) 4.44
Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet (1999) 3.54
Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg (2011) 2.01
Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg (2009) 1.94
Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology (2003) 1.65
Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med (2008) 1.49
Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol (2006) 1.45
In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines. Br J Cancer (1999) 1.42
Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med (1994) 1.20
Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg (2008) 1.07
The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int (2009) 1.03
Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther (2010) 1.03
Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. BMC Gastroenterol (2013) 0.93
Resection of hepatocellular carcinoma without cirrhosis. Ann Surg (2012) 0.87
Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol (2006) 0.83
Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: a meta-analysis of randomized controlled trials. BMC Gastroenterol (2012) 0.83
Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial. World J Surg (2013) 0.82
Safety and efficacy of trisectionectomy for hepatocellular carcinoma. ANZ J Surg (2011) 0.81
Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine 131-labeled iodized oil. Cancer (1991) 0.81
Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution. Cancer Chemother Pharmacol (1992) 0.79
Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis. Int J Clin Oncol (2011) 0.77